EPI2ME Labs 22.07.02 Release

By Stephen Rudd
Published in Software Releases
July 27, 2022
1 min read

Dear Nanopore Community,

Our workflow for SARS-CoV-2 genome analysis, wf-artic, has been updated to version v0.3.18. This release includes updates to the Pangolin and Nextclade software components and ensures that the most recent SARS-CoV-2 strains can be reported. Further details may be found from the workflow changelog. This update is synchronised with an EPI2ME release. EPI2ME Fastq QC+ARTIC+NextClade is now available with version v2022.07.19.

We have released a freshly named workflow, wf-transcriptomes, with version v0.1.4 that replaces the earlier wf-isoforms product. Included in this release is new functionality for fusion transcript detection - these analyses are performed using the JAFFA software.

Example datasets are now provided through the EPI2ME Labs GUI for the wf-artic and wf-transcriptomes workflows. Press the “Workflow demo” button at the top of the workflow page and the workflow design will be populated with a small pre-packaged dataset. These updates require an update to both the EPI2ME Labs software (v3.1.3) and the epi2melabs-notebook container (v1.1.30).

We look forwards to any feedback and welcome suggestions and recommendations for future workflows, tutorials, or new functionality to include in EPI2ME Labs.


Tags

#notebooks#nextflow#workflows#releases

Share

Stephen Rudd

Stephen Rudd

Director, Bioinformatics Product

Related Posts

EPI2ME 24.03-01 Release
March 06, 2024
2 min

Quick Links

TutorialsWorkflowsOpen DataContact

Social Media

© 2020 - 2024 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor, MinION, MinIT, MinKNOW, Plongle, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.